# US 2020/0384112 A1 · Saposin c pharmaceutical compositions and methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0384112 A1
- Document ID: US20200384112A1
- Status: Published application
- Kind: A1
- Application number: 16/865,168
- Filed: 2020-05-01
- Published: 2020-12-10
- Earliest claimed: 2018-03-23
- Assignees: Bexion Pharmaceuticals Inc.
- Applicants: Bexion Pharmaceuticals Inc.
- Inventors: Ellen K. Monson; Xiaochen Wei; Ray Takigiku; Charles A. Cruze, III; Joseph W. Wyse
- Web page: https://patentgrep.com/patent/US20200384112A1

## CPC

- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/18: Growth factors; Growth regulators
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- C07K 14/4705: {stimulating, promoting or activating activity}
- C12Q 1/40: involving amylase
- A61K 38/1709: {from mammals}
- C12Q 2334/22: 4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.

## Claims

### Claim at position 1

1-41. (canceled)

### Claim 42

A composition comprising:
a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 with zero to four amino acid insertions, substitutions, or deletions;
a phosphatidylserine lipid;
a buffer at pH 5.0 to 8.0;
trehalose; and
water,
wherein the polypeptide is at a concentration of 0.4 to 5.0 mg/ml,
wherein the molar ratio of the phosphatidylserine lipid to the polypeptide is in the range of 8:1 to 20:1, and
wherein the phosphatidylserine lipid and the polypeptide are associated together in the form of vesicles suspended in the water.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the majority of the vesicles in the composition have diameters, as measured by a dynamic light scattering technique, of less than 100 nm.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the trehalose is at a concentration of 1.5 to 9 percent w/v.

### Claim 45 (depends on 43)

The composition of claim 43, wherein the trehalose is at a concentration of (5±1) percent w/v.

### Claim 46 (depends on 43)

The composition of claim 43, wherein the polypeptide's amino acid sequence comprises SEQ ID NO: 1.

### Claim 47 (depends on 43)

The composition of claim 43, wherein the phosphatidylserine lipid comprises one or more of dioleoyl phosphatidylserine (DOPS), dihexanoyl phosphatidylserine, dioctanoyl phosphatidylserine, didecanoyl phosphatidylserine, dilauroyl phosphatidylserine, dimyristoyl phosphatidylserine, dipalmitoyl phosphatidylserine, palmitoyl-oleoyl phosphatidylserine, 1-stearoyl-2-oleoyl phosphatidylserine, or diphytanoyl phosphatidylserine, and wherein the phosphatidylserine lipid is in either a salt or a non-salt form.

### Claim 48 (depends on 43)

The composition of claim 43, wherein the phosphatidylserine lipid comprises DOPS in a salt form.

### Claim 49 (depends on 43)

The composition of claim 43, wherein the phosphatidylserine lipid comprises DOPS in the form of a salt with a cation.

### Claim 50 (depends on 49)

The composition of claim 49, wherein the cation is sodium ion.

### Claim 51 (depends on 48)

The composition of claim 48, wherein the polypeptide's amino acid sequence comprises SEQ ID NO: 1.

### Claim 52 (depends on 43)

The composition of claim 43, further comprising t-butyl alcohol at a concentration of less than 2 percent w/w.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the t-butyl alcohol is present at a concentration of less than 0.5 percent w/w.

### Claim 54 (depends on 51)

The composition of claim 51, further comprising t-butyl alcohol at a concentration of less than 2 percent w/w.

### Claim 55 (depends on 51)

The composition of claim 51, wherein the trehalose is at a concentration of 1.5 to 9 percent w/v.

### Claim 56 (depends on 51)

The composition of claim 51, wherein the trehalose is at a concentration of (5±1) percent w/v.

### Claim 57 (depends on 55)

The composition of claim 55, wherein the polypeptide is at a concentration of 1.9 to 2.5 mg/ml and the DOPS is at a concentration of 2.0 to 2.8 mg/ml.

### Claim 58 (depends on 43)

The composition of claim 43, wherein the buffer is Tris buffer, citrate buffer or acetate buffer, and is at a concentration of 10 to 50 mM.

### Claim 59 (depends on 49)

The composition of claim 49, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1 and is at a concentration of 1.9 to 2.5 mg/ml.

### Claim 60 (depends on 59)

The composition of claim 59, wherein the molar ratio of DOPS to polypeptide is in the range of 11:1 to 13:1.

### Claim 61

An in vitro method for assaying potency of a composition comprising saposin C and an anionic phospholipid, the method comprising:
carrying out a first assay that comprises contacting the composition with glucocerebrosidase and 4-methylumbelliferyl-β-D-glucopyranoside (4-MUG);
carrying out a control assay that comprises contacting a reference standard composition with glucocerebrosidase and 4-MUG;
determining the level of 4-methylumbellierone (4-MU) formed as a result of cleavage of 4-MUG in the first assay;
determining the level of 4-MU formed as a result of cleavage of 4-MUG in the control assay; and
comparing the level of 4-MU formed in the first assay to the level of 4-MU in the control assay, thereby determining the relative potency of the composition.
